The performance of companies tied to blockbuster drugs like Viagra presents a nuanced investment picture. While the initial boom of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the expiry in key markets has introduced considerable uncertainty . Investors are now assessing the effect of lower-cost alternativ